Sunday 25 October
Virtual Lunch Symposium
Innovative therapeutic alternatives for RA, PsA, AS and nr-axSpA: Individualising the treatment approach
This Lilly satellite symposium will explore the integrated approach to improving our understanding of the impact of specific domains of chronic systemic disease, like Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis on the every-day-life of our patients.
The expert panel of presenters will review the recent improvements in patient management, as well as those areas that remain open to improvement, in the context of the current and emerging molecular mechanism of JAK inhibition and IL17 inhibition.
The symposium will be chaired by Prof. Kunihiro Yamaoka (Tokyo, Japan) and will address two key areas:
1. Emerging learnings in PsA, AS and nr-axSpA: From clinical trials to clinical practice
Speaker: Prof. Lars Erik Kristensen (Copenhagen, Denmark) will share the most up-to-date data for Ixekizumab from the SPIRIT and COAST trial programmes and discuss how these results inform the management of patients with Psoriatic Arthritis and Axial Spondyloarthritis in clinical practice.
2.Challenges and opportunities in the treatment of RA: The role of JAK inhibitors
Speaker: Prof. Andrew Ostör (Melbourne, Australia) will share the most up-to-date data for Baricitinib, elaborating on its use in daily practice, and discuss the placement of JAK inhibitors in the treatment algorithm for Rheumatoid Arthritis.
The symposium will close with a panel discussion for any unanswered questions.
We hope that you find this symposium a valuable forum for discussing the impact and areas of improvement in the treatment of rheumatic disease.